	US 11,851,495 B2
	TRAILR2 CDH17 binding molecules for the treatment of cancer
Klaus-Peter Kuenkele, Langenbach (DE); Timothy Fenn, Greenwich, CT (US); Juan Manuel Garcia-Martinez, Vienna (AT); Jason Ho, Collegeville, PA (US); Christian Koessl, Kramsach (AT); Saurabh Sen, Sandy Hook, CT (US); Vladimir Voynov, Danbury, CT (US); and Andreas Wernitznig, Vienna (AT)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Oct. 30, 2020, as Appl. No. 17/084,881.
Application 17/084,881 is a division of application No. 15/850,895, filed on Dec. 21, 2017, granted, now 10,858,438.
Claims priority of provisional application 62/437,770, filed on Dec. 22, 2016.
Claims priority of application No. 17155973 (EP), filed on Feb. 14, 2017.
Prior Publication US 2021/0095038 A1, Apr. 1, 2021
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2866 (2013.01) [A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/73 (2013.01)]

36 Claims

1. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a binding molecule that binds to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17), said binding molecule comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:196 or SEQ ID NO:197; and a light chain comprising the amino acid sequence of SEQ ID NO:203, wherein the cancer is colorectal cancer (CRC), gastric cancer (GC), pancreatic cancer (PAC), esophageal cancer or a neuroendocrine tumor.